Copyright
©The Author(s) 2017.
World J Gastroenterol. Dec 21, 2017; 23(47): 8395-8404
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8395
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8395
Table 4 Multivariate analysis of the clinical factors predictive of complete symptom resolution within one week based on dexlansoprazole and esomeprazole administration
| Time | PPI | Clinical factors | CSR | Coefficient of variation | Odds ratio (95%CI) | P value |
| Day 1 | Dexlansoprazole | Null | ||||
| Esomeprazole | Female | 15.80% | -1.249 ± 0.543 | 0.285 (0.103-0.789) | 0.022 | |
| Day 3 | Dexlansoprazole | Null | ||||
| Esomeprazole | Female | 18.40% | -1.254 ± 0.519 | 0.287 (0.099-0.832) | 0.016 | |
| Day 7 | Dexlansoprazole | Null | ||||
| Esomeprazole | Null |
- Citation: Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK, Taiwan Acid-Related Disease Study Group. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol 2017; 23(47): 8395-8404
- URL: https://www.wjgnet.com/1007-9327/full/v23/i47/8395.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i47.8395